

## CURRICULUM VITAE

### Name

Academic Title	First Name	Family Name	Qualifications
Physician	Clara	Montenegro del Pozo	Degree in Medicine



### Current Position and Discipline

Ophthalmology Resident from Sept/2020

### Medical Licence/Registration Number and Issue Date

141409495, 08/12/2020

### Current Employer

<b>Institution</b>	Reina Sofia University Hospital		
<b>Department</b>	Ophthalmology Unit		
<b>Address</b>	Av. Menendez Pidal, s/n, 14004 Córdoba		
<b>Telephone</b>	+34 685225790	<b>Fax</b>	-
<b>Email</b>	montenegrodelpozo@gmail.com		

### Medical Career History

Dates from to	Position	Institution and Department
SEP/2020-Nowdays	Ophthalmology Residency Program	Andalusian Health Service Reina Sofia University Hospital, Córdoba, Spain

### Education

Year	Qualification	Academic Institution, City and Country Where Obtained
2013-2019	Medicine University Degree	University of Seville, Seville, Spain
2020-2022	Translational Biomedical Research Master Degree	IMIBIC and University of Cordoba, Cordoba, Spain

### Experience in Clinical Trials and Investigation Projects

Year	Study	Role
2020	Clinical Trial Adequate Study Phase 4: Randomized single-blind clinical trial to evaluate the free latanoprost/timolol (Fixaprost ®) compared to preserved bimatoprost/timolol (Ganfort ®) in patients with open-angle glaucoma or ocular hypertension.	Sub-Investigator
2021	Clinical Trial Théa Study Phase 3: Efficacy and safety assessment of T4030 Eye Drops vs Ganfort UD in Ocular Hypertensive of glaucomatous patients.	Sub-Investigator
2022	Retrospective descriptive observational Study: Observational study of refraction under cycloplegia in children using image analysis and non-invasive tests.	Principal Investigator

2022	Pivotal Study Phase 3b: Efficacy and safety of Izokibep on subjects with posterior, intermedious, non infectious or panuveitis.	Investigator
2022	A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD)	Investigator
2022	Effects Of Semaglutide On Functional Capacity In Patients With Type 2 Diabetes And Peripheral Arterial Disease. Novo Nordisk. Phase 3b. Code: NN9535-4533 (STRIDE).	Collaborator Investigator
2022	A Heart Disease Study Of Semaglutide In Patients With Type 2 Diabetes. Novo Nordisk. Phase 3. Code: EX9924-4473 (SOUL).	Collaborator Investigator
2022	A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial Of Trastuzumab Deruxtecan (DS-8201a) In Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer With Brain Metastases And/Or Leptomeningeal Carcinomatosis. MEDSIR. Phase 2. Code: Medopp243 (DEBBRAH).	Collaborator Investigator
2022	A Phase 3 Study Of Erdafitinib Compared With Vinflunine Or Docetaxel Or Pembrolizumab In Subjects With Advanced Urothelial Cancer And Selected FGFR Gene Aberrations. Janssen-Cilag International NV. Phase 3. Code: 42756493BLC3001 (THOR).	Collaborator Investigator
2022	Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302). QED Therapeutics, Inc. Phase 3. Code: QBGJ398-302 (PROOF).	Collaborator Investigator
2022	A Phase 3, Single Arm Study Of Mirvetuximab Soravtansine In Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression. Immunogen, Inc. Phase 3. Code: SORAYA.	Collaborator Investigator
2022	An Open-Label, Randomized, Controlled Phase 3 Study Of Enfortumab Vedotin In Combination With Pembrolizumab Versus Chemotherapy Alone In Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer. Seagen. Phase 3. Code: SGN22E-003 (EV-302).	Collaborator Investigator
2022	Open-Label, Multicenter, Non-Randomized, Phase 2 Study To Determine The Safety, Tolerability And Efficacy Of Encorafenib Given In Combination With Binimetinib In Patients With BRAFV600E-Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC). ARRAY Biopharma. Phase 2. Code: Array 818-202.	Collaborator Investigator
2022	A Phase II, Multicenter, Open-Label Study To Evaluate The Efficacy And Safety Of Trastuzumab Deruxtecan (T-Dxd, DS-8201a) For The Treatment Of Selected HER2-Expressing Tumors (DESTINY-PanTumor02). Astrazeneca. Phase 2. Code: D967VC00001 (DESTINY PANTUMOR02).	Collaborator Investigator
2022	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy In First-Line Treatment Of Participants With Unresectable Or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302). Incyte. Phase 3. Code: FIGHT-302.	Collaborator Investigator

2022	A Randomized, Open-Label, Phase 3 Trial Of Tisotumab Vedotin Vs Investigator's Choice Chemotherapy In Secondor Third-Line Recurrent Or Metastatic Cervical Cancer. Seagen, Inc. Phase 3. Code: SGNTV-003.	Collaborator Investigator
2022	A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) Alone And In Combination With Defactinib (FAK Inhibitor) In Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201). Verastem, Inc; ENGOT; GOG Foundation. Phase 2. Code: VS-6766-201.	Collaborator Investigator
2022	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatments And Combinations In Patients With Urothelial Carcinoma. F. Hoffmann-La Roche Ltd. Phase 1B/2. Code: WO39613 (MORPHEUS-UC).	Collaborator Investigator
2022	A Phase 2, Single Arm Study Of Mirvetuximab Soravtansine In Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, Or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression. Immunogen. Phase 2. Code: IMGN853-0419 (PICCOLO).	Collaborator Investigator
2022	A Phase 3, Randomized, Double-Blind Study Of Encorafenib And Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab In Participants With BRAFV600e/K Mutation-Positive Metastatic Or Unresectable Locally Advanced Melanoma. Pfizer. Phase 3. Code: C4221016 (STARBOARD).	Collaborator Investigator
2022	A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase 3 Study Of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy In Subjects With Previously Untreated Advanced Gastric Or Gastroesophageal Junction Cancer With FGFR2b Overexpression. AMGEN. Phase 3. Code: 20210096 FORTITUDE-101.	Collaborator Investigator
2022	A Phase 3, Randomized, Multi-Center, Open-Label Study Of Trastuzumab Deruxtecan (T-Dxd) Versus Investigators Choice Chemotherapy In HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed On Endocrine Therapy In The Metastatic Setting (DESTINY-Breast06). Astrazeneca. Phase 3. Code: D9670C00001 (DESTINY-BREAST06).	Collaborator Investigator
2022	Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapy. Immunogen. Phase 2. Code: IMGN853-0420.	Collaborator Investigator
2022	Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group. Pierre Fabre Médicament. Phase 3. Code: W00090GE303 / EORTC-2139-MG (COLUMBUS-AD).	Collaborator Investigator
2022	A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer. Genmab A/S. Phase 1b/2. Code: GCT1015-05/ENGOT-cx8.	Collaborator Investigator

2022	A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours(TROPION-PanTumor03). AstraZeneca. Phase 2. Code: D926UC00001 (TROPION).	Collaborator Investigator
2022	A Phase 3, Randomized, Double-blind Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced G/GEJ Cancer With FGFR2b Overexpression.	Collaborator Investigator

## Courses

Year	Qualification	Academic Institution, City and Country Where Obtained
2020	Functioning, regulation and composition of the Committee for the Integrity of the Investigation Training	IMIBIC, Cordoba, Spain
2020	ICH Good Clinical Practice E6	The Global Health Network
2020	Environmental and Energy Management Training	Reina Sofia University Hospital, Cordoba, Spain
2020	Age-Related Macular Degeneration Basic Course Training	Puerto Real University Hospital, Cadiz, Spain
2020	Impact of Health Information Technologies on Patient Safety Training	Reina Sofia University Hospital, Cordoba, Spain
2021	Foundations of Cornea and Phaco-Implant-Refractive Surgery	SECOIR, Madrid, Spain
2021	Advanced Training in Animal Protection and Experimentation	IFAPA, Cordoba, Spain
2021	V Actualization Course for MIR and POSTMIR. Foundations of Cornea and Phaco-Implant-Refractive Surgery	SECOIR, Toledo, Spain
2021	Safety at work in laboratories	Quirón Prevención, Madrid, Spain
2021	Storage and handling of chemicals	Quirón Prevención, Madrid, Spain
2021	Lens surgery with multifocal lenses: which, how and in which patients?	SIREV, Spain
2021	Introductory course in ophthalmology for first-year residents	SAO, Seville, Spain
2021	Training Initiation to Phaco: first steps in cataract surgery	Retina Academy, Spain
2021	Age-Related Macular Degeneration Basic Course Training II	Puerto Real University Hospital, Cadiz, Spain
2021	Initiation to refractive surgery for ophthalmology residents.	La Arruzafa Hospital, Cordoba, Spain
2021	Radiation protection for Residents	IAVANTE, Spain
2022	Focus on Refractive: Refractive Surgery	Zeiss

2022	Inflammation and Infection in the Cornea and Ocular Surface	Esteve, Spain
2022	Good Clinical Practice E6 (R2)-The Global Health Network	Transcelerate Biopharma
2022	Keratoconus Surgery Workshops: Keratoconus Management. Update on intrastromal rings	La Arruzafa Hospital, Cordoba, Spain
2022	International Thyroid Eye Disease Society. Virtual session	ITEDS
2022	Workshop on Glaucoma Surgery. i-Stent Glaukos Implant	Glaukos, Córdoba, Spain
2022	Update on the diagnosis and management of patients without optic neuropathy	Esmon, Spain

### Congress

2020	Annual monograph on retina initiation aimed at first and second year ophthalmology residents	CEM junior
2021	IX Online Conference of the Association of Young Spanish Ophthalmologists	AJOE, SEO
2021	XXX SECPOO National Congress	SECPOO
2021	VII International Congress of research in retina and vision.	SIREV
2021	LIII Congress of the Andalusian Society of Ophthalmology	SAO
2021	XIX ARI 2021-Online.	ARI
2021	Foundations of Cornea and Phaco-Implant-Refractive Surgery	SECOIR, Madrid, Spain
2021	Advanced Training in Animal Protection and Experimentation	IFAPA, Cordoba, Spain
2021	V Actualization Course for MIR and POSTMIR. Foundations of Cornea and Phaco-Implant-Refractive Surgery	SECOIR, Toledo, Spain
2021	Annual monograph on retina initiation aimed at first and second year ophthalmology residents	CEM junior
2021	Arruzafa Forum. Survival manual in medical retina and vitreoretinal surgery	La Arruzafa Hospital
2022	X Online Conference of the Association of Young Spanish Ophthalmologists	SEO, AJOE
2022	LIV Congress of the Andalusian Society of Ophthalmology	SAO
2022	Annual meeting for andalusian ophthalmology residents	Esteve

2022	IV Andalusian Strabology Meeting	SAO, Granada, Spain
2022	98 <sup>th</sup> Ophthalmology Spanish Society Congress	SEO, Pamplona, Spain
2022	Arruzafa Forum. How to survive glaucoma	La Arruzafa Hospital, Cordoba, Spain
2022	XX ARI 2021-Online.	ARI
2022	III Andalusian Neuroophthalmology Meeting	SAO, Málaga, Spain

## Languages

Mother Language	Spanish
Other Languages	English. Level B2. First Certificate in English (Cambridge English)
Other Languages	French. Basic level.

## Publications and Communications

Algorithms in Ophthalmology for Primary Care. Chapter 2: Visual Field Alteration. Ophthalmology Unit. Reina Sofia University Hospital, Córdoba, Spain. ISBN: 978-84-124742-0-6
Poster "Choroidal tuberculoma as a form of presentation of ocular tuberculosis". LIII Congress of the Andalusian Society of Ophthalmology.
Poster "Kaposi varicelliform eczema: about a case". LIII Congress of the Andalusian Society of Ophthalmology.
Poster "elastic pseudoxanthoma". LIII Congress of the Andalusian Society of Ophthalmology.
A case report: ocular cicatricial pemphigoid. The Théa international contest of clinical cases in Pathologies of the eye (TROPY)
Oral Communication: "Neovascular membrane in childhood: diagnostic and therapeutic approach of a case". 98 <sup>th</sup> Ophthalmology Spanish Society Congress